--- title: "Cue Biopharma (NASDAQ:CUE) Trading Down 3.8% - Should You Sell?" type: "News" locale: "en" url: "https://longbridge.com/en/news/295482934.md" description: "Cue Biopharma (NASDAQ:CUE) shares fell 3.8% to $26.10, with trading volume up 85%. Despite a recent earnings beat and positive hedge fund activity, the stock maintains a consensus 'Sell' rating from analysts. Weiss Ratings downgraded the stock, while Wall Street Zen upgraded it to 'Buy'. The company reported a loss of $1.08 per share but exceeded revenue expectations." datetime: "2026-08-11T04:20:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295482934.md) - [en](https://longbridge.com/en/news/295482934.md) - [zh-HK](https://longbridge.com/zh-HK/news/295482934.md) generator: "portal-rs" --- # Cue Biopharma (NASDAQ:CUE) Trading Down 3.8% - Should You Sell? Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) fell 3.8% during mid-day trading on Monday . The company traded as low as $24.80 and last traded at $26.10. Approximately 315,940 shares changed hands during mid-day trading, an increase of 85% from the average session volume of 170,606 shares. The stock had previously closed at $27.12. Get **Cue Biopharma** alerts: ## Analyst Ratings Changes Several equities research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Cue Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, May 18th. Wall Street Zen raised shares of Cue Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, June 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of "Sell". **Check Out Our Latest Stock Report on CUE** ## Cue Biopharma Price Performance The firm's fifty day moving average price is $29.31 and its two-hundred day moving average price is $154.54. The stock has a market cap of $109.62 million, a price-to-earnings ratio of -4.67 and a beta of 2.47. Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.30) by $2.22. The company had revenue of $5.69 million for the quarter, compared to analysts' expectations of $2.50 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%. ## Hedge Funds Weigh In On Cue Biopharma Hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock valued at $57,000 after purchasing an additional 73,000 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Cue Biopharma during the 3rd quarter worth approximately $62,000. Stifel Financial Corp boosted its stake in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company's stock worth $75,000 after buying an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its stake in shares of Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock worth $135,000 after buying an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its position in Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company's stock worth $215,000 after purchasing an additional 93,333 shares during the last quarter. 35.04% of the stock is owned by hedge funds and other institutional investors. ## Cue Biopharma Company Profile (Get Free Report) Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation. Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies. ## Further Reading - Five stocks we like better than Cue Biopharma - SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat - 3 Dividend Champion Utilities for a Market That Can't Sit Still - These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI - First Solar’s Profit Engine Faces a New Policy Test in Washington *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Cue Biopharma Right Now? Before you consider Cue Biopharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cue Biopharma wasn't on the list. While Cue Biopharma currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CUE.US](https://longbridge.com/en/quote/CUE.US.md) - [SF.US](https://longbridge.com/en/quote/SF.US.md) - [TCBI.US](https://longbridge.com/en/quote/TCBI.US.md) - [SOUN.US](https://longbridge.com/en/quote/SOUN.US.md) - [FSLR.US](https://longbridge.com/en/quote/FSLR.US.md) - [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/en/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md) - [SOUNW.US](https://longbridge.com/en/quote/SOUNW.US.md) ## Related News & Research - [Shao-Lee Lin Discloses Investment at Cue Biopharma with 6.2% Stake](https://longbridge.com/en/news/296653801.md) - [Cue Biopharma Chief Executive Officer Sold Shares Worth Over $1.6M](https://longbridge.com/en/news/295986047.md) - [Cisco and Supermicro Are Joining Forces in the AI Data Center Boom. How to Play Their Stocks Now.](https://longbridge.com/en/news/297534295.md) - [Church's Texas Chicken's China debut drew 2-hour lines — and $22 offers to wait in them](https://longbridge.com/en/news/297600833.md) - [Mutual Insurance Co Donegal Acquires 10,000 Shares of Donegal Group (NASDAQ:DGICA) Stock](https://longbridge.com/en/news/297791553.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**